PURAPLY®AM & PURAPLY®XT SCIENTIFIC DATA

Discover the antimicrobial effectiveness within PuraPly®AM and PuraPly®XT in nonclinical studies.

ANTIMICROBIAL EFFECTIVENESS AND LOW CYTOTOXICITY

In an in vitro and in vivo nonclinical study to evaluate the antimicrobial capabilities of PuraPly®AM and PuraPly®XT and several other antimicrobial and collagen products against MRSA USA300:

  • PuraPly®AM and PuraPly®XT demonstrated the highest antimicrobial activity against MRSA compared to Aquacel Ag and PriMatrix Ag
  • PuraPly®AM and PuraPly®XT were able to substantially reduce MRSA in vivo without impairing the wound healing process2
  • PuraPly®AM and PuraPly®XT were noncytotoxic, with no detrimental effects in vitro on fibroblast proliferation and viability2
In vivo: Substantial MRSA reduction1

> 99%

PuraPly AM MRSA reduction from
post-debridement baseline1

MRSA Counts (in vivo)
*P<0.05 vs Aquacel Ag and vs PriMatrix Ag **P<0.05 vs pre- and post-debridement baselines
In vitro: Minimal cytotoxicity1

94.41%

fibroblast viability

at 48 hours for PuraPly AM

BROAD-SPECTRUM ANTIMICROBIAL EFFECTIVENESS

In a United States Pharmacopeia Antimicrobial Effectiveness Test, PuraPly AM effectively reduced concentrations of the following microbes at days 7, 14, and 282:

PuraPly AM reduced concentrations of Aspergillus niger, MRSA, Candida albicans, Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli in wounds

SUPPORTING WOUND CLOSURE IN REAL-WORLD STUDIES

See how PuraPly AM supported healing in real-world studies, or contact an Organogenesis Tissue Regeneration Specialist to see how PuraPly®AM and PuraPly®XT can help your practice.

Contact us

Please refer to the PuraPly AM Instructions for Use and PuraPly XT Instructions for Use for complete prescribing information.

REFERENCES:

  1. Davis SC, et al. Int Wound J. 2021 May 6. doi:10.1111/iwj.13600. Epub ahead of print. PMID: 33955663.
  2. Data on file. USP Antimicrobial Effectiveness Test. Organogenesis Inc.